Mycophenolic acid is an immunosuppressant used to prevent organ transplant rejections. Mycophenolic acid is a potent immunosuppressant agent that inhibits de novo purine biosynthesis.
- Mechanism
- Curator reviewed · 5 references
Mycophenolic acid is a selective noncompetitive and reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH), that blocks the conversion of inosine-5-phosphate and xanthine-5-phosphate to guanosine-5-phosphate. By inhibiting IMPDH, mycophenolic acid interferes with the de novo pathway of guanosine nucleotide synthesis without incorporation into DNA. While other cell types are able to use salvage pathways, T- and B-lymphocyte proliferation is a mechanism heavily dependent on the de novo synthesis of purines. Therefore, mycophenolic acid has potent cytostatic effects on T- and B- and lymphocytes. Mycophenolic acid also suppresses antibody formation by B-lymphocytes and prevents the glycosylation of lymphocyte and monocyte glycoproteins involved in intercellular adhesion to endothelial cells.
- Primary indication
- Mycophenolic acid is an antimetabolite immunosuppressant indicated for prophylaxis of organ rejection in adult patients receiving kidney transplants and in pediatric patients at least 5 years of age and older who are at least 6...Curator reviewed · 2 structured indications
- Formula / weight
- C17H20O6 · 320.3371 g/mol (avg)
- First approval
- Canada, 2014 · United States, 2004
- Also known as
- Mycophenolate
- Code names
- 68618 · NSC-129185
- Brand names
Resolves to
HPNSFSBZBAHARI-RUDMXATFSA-NSMILESCOC1=C(C\C=C(/C)CCC(O)=O)C(O)=C2C(=O)OCC2=C1CWhat you can answer from here — as of September 23, 2026
Which drugs share a target with Mycophenolic acid, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account